S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may stop
the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving cetuximab together with
paclitaxel, carboplatin, and bevacizumab may kill more tumor cells. This phase II trial is
studying how well giving cetuximab together with paclitaxel, carboplatin, and bevacizumab
works in treating patients with advanced non-small cell lung cancer